Skip to main content
. 2021 Jan 19;124(6):1037–1048. doi: 10.1038/s41416-020-01225-5

Table 2.

Clinical trials of CD3+ bispecific T-cell redirectors for haematological cancers.

Targets Clinical trial Phase Clinical trial identifier Disease indication(s) Organisation(s) Antibody
CD3 × CD19 Launched NCT01207388 B-cell precursor ALL Amgen Blinatumomab; Blincyto; AMG 103
CD3 × CD19 Phase 1 NCT03571828 B-cell NHL; DLBCL; MCL; FL Amgen AMG 562
CD3 × CD19 Phase 1 NCT04056975 B-cell lymphoma Generon A-319
CD3 × CD19 Phase 1 CTR20191955 B-cell lymphoma Lvzhu Biopharmaceutical K193
CD3 × CD20 Phase 1/2

NCT02651662

NCT02290951

NCT03888105

B-cell NHL; CLL Regeneron REGN1979
CD3 × CD20 Phase 1 NCT04082936 B-cell NHL; DLBCL; MCL; FL; MZL IGM Biosciences IGM-2323
CD3 × CD20 Phase 1 NCT02924402 B-cell NHL; CLL; small lymphocytic lymphoma Xencor Plamotamab; XmAb13676
CD3 × CD20 Phase 1/2

NCT02500407

NCT03671018

NCT03677141

NCT03677154

B-cell NHL; CLL; DLBCL Genentech; Hoffmann-La Roche Mosunetuzumab; BTCT4465A; RO7030816
CD3 × CD20 Phase 1/2 NCT03625037 DLBCL; MCL; FL Genmab GEN3013
CD3 × CD20 Phase 1

NCT03075696

NCT03533283

NCT04313608

NCT04246086

NCT04077723

NCT03467373

B-cell NHL; DLBCL; FL Hoffmann-La Roche Glofitamab; RO7082859
CD3 × CD20 Phase 1

NCT00244946

NCT00938626

B-cell NHL; multiple myeloma; plasma cell neoplasm Barbara Ann Karmanos Cancer Institute CD20Bi-ATC
CD3 × CD33 Phase 1 NCT03915379 Myelodysplastic syndrome; AML Janssen JNJ-67571244
CD3 × CD33 Phase 1 NCT02520427 Myelodysplastic syndrome; AML Amgen AMG 330
CD3 × CD33 Phase 1 NCT03224819 AML Amgen AMG 673
CD3 × CD33 Phase 1 NCT03516760 AML Celgene GEM333
CD3 × CD33 Phase 1

NCT04128423

NCT03144245

NCT03516591

Myelodysplastic syndrome; AML Amphivena Therapeutics AMV564
CD3 × CD38 Phase 1/2 NCT03309111 Multiple myeloma Glenmark Pharmaceuticals GBR 1342
CD3 × CD38 Phase 1 NCT03445663 Multiple myeloma Amgen AMG 424
CD3 ×  CD123 Phase 1 NCT03647800 Myelodysplastic syndrome; AML Aptevo Therapeutics APVO436
CD3 ×  CD123 Phase 1/2

NCT04158739

NCT02152956

NCT03739606

AML; ALL; other haematologic malignancies MacroGenics Flotetuzumab; MGD006
CD3 ×  CD123 Phase 1 NCT02730312 B-cell ALL; AML; CLL; blastic plasmacytoid dendritic cell neoplasm Xencor Vibecotamab; XmAb14045
CD3 ×  CD123 Phase 1/2 NCT03594955 B-cell ALL; AML; myelodysplastic syndrome Sanofi SAR440234
CD3 × CD123 Phase 1 NCT02715011 AML Janssen JNJ-63709178
CD3 ×  BCMA Phase 1

NCT02514239

NCT03836053

Multiple myeloma Boehringer Ingelheim; Amgen BI 836909; AMG 420
CD3 ×  BCMA Phase 1 NCT03287908 Multiple myeloma Amgen AMG 701
CD3 ×  BCMA Phase 1 NCT03933735 Multiple myeloma AbbVie; TeneoBio TNB-383B
CD3 ×  BCMA Phase 1 NCT03269136 Multiple myeloma Pfizer PF-06863135
CD3 ×  BCMA Phase 1

NCT03145181

NCT04108195

Multiple myeloma Janssen JNJ-64007957
CD3 ×  BCMA Phase 1 NCT03486067 Multiple myeloma Celgene CC-93269
CD3 ×  BCMA Phase 1/2 NCT03761108 Multiple myeloma Regeneron; Sanofi REGN5458
CD3 ×  BCMA Phase 1 NCT04083534 Multiple myeloma Regeneron; Sanofi REGN5459
CD3 × BCMA × ALB Phase 1/2 NCT04184050 Multiple myeloma Harpoon Therapeutics; AbbVie HPN217
CD3 × CLEC12A Phase 1 NCT03038230 AML Merus Tepoditamab; MCLA-117
CD3 × FcRH5 Phase 1 NCT03275103 Multiple myeloma Genentech RO7187797; BFCR4350A
CD3 × FLT3 Phase 1 NCT03541369 AML Amgen AMG 427
CD3 ×  GPRC5D Phase 1

NCT03399799

NCT04108195

Multiple myeloma Janssen JNJ-64407564

BCMA B-cell maturation antigen, ALB albumin, CLEC12A C-type lectin domain family 12 member A, FcRH5 Fc receptor-homology 5, FLT3 Fms-like tyrosine kinase 3, GPRC5D G protein-coupled receptor class C group 5 member D, AML acute lymphoblastic leukaemia, NHL non-Hodgkin lymphoma, DLBCL diffuse large B-cell lymphoma, MCL mantle cell lymphoma, FL follicular lymphoma, CLL chronic lymphocytic leukaemia, MZL marginal zone lymphoma, AML acute myeloid leukaemia.